Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish

Corina Anastasaki, Katherine A Rauen, E. Elizabeth Patton

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAFCFC mutations.

Original languageEnglish (US)
Pages (from-to)546-552
Number of pages7
JournalDMM Disease Models and Mechanisms
Volume5
Issue number4
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Zebrafish
Phenotype
Skin
Phosphotransferases
Alleles
Gastrulation
Mutation
Germ-Line Mutation
Neoplasms
Embryonic Structures
Tissue
Defects
PD 0325901
Cardiofaciocutaneous syndrome

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. / Anastasaki, Corina; Rauen, Katherine A; Patton, E. Elizabeth.

In: DMM Disease Models and Mechanisms, Vol. 5, No. 4, 07.2012, p. 546-552.

Research output: Contribution to journalArticle

@article{d8041f997beb49b6b23947929b36c992,
title = "Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish",
abstract = "Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAFCFC mutations.",
author = "Corina Anastasaki and Rauen, {Katherine A} and Patton, {E. Elizabeth}",
year = "2012",
month = "7",
doi = "10.1242/dmm.008672",
language = "English (US)",
volume = "5",
pages = "546--552",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "4",

}

TY - JOUR

T1 - Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish

AU - Anastasaki, Corina

AU - Rauen, Katherine A

AU - Patton, E. Elizabeth

PY - 2012/7

Y1 - 2012/7

N2 - Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAFCFC mutations.

AB - Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAFCFC mutations.

UR - http://www.scopus.com/inward/record.url?scp=84863494976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863494976&partnerID=8YFLogxK

U2 - 10.1242/dmm.008672

DO - 10.1242/dmm.008672

M3 - Article

C2 - 22301711

AN - SCOPUS:84863494976

VL - 5

SP - 546

EP - 552

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 4

ER -